Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana to Participate in Citi's 2018 Global Healthcare Conference
EDINBURGH, United Kingdom , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz , Chief Financial Officer, will host one-on-one meetings
View HTML
Toggle Summary NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update
Favorable Data Presented at ESMO on NUC-1031 (Acelarin ® ) and NUC-3373 First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer Initiation of Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer and Phase I Study of NUC-7738 Expected by End of 2018
View HTML
Toggle Summary NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference
EDINBURGH, United Kingdom , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Don Munoz , Chief Financial Officer, will host one-on-one meetings at
View HTML
Toggle Summary NuCana to Participate in the Jefferies 2018 London Healthcare Conference
EDINBURGH, United Kingdom , Nov. 07, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief
View HTML
Toggle Summary NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer
NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU EDINBURGH, United Kingdom , Nov. 01, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the first patients have been enrolled in the NuTide:302 Study.
View HTML
Toggle Summary NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018
Single-Agent Anti-Cancer Activity Observed in Patients with Advanced Solid Tumors NUC-3373 Demonstrates Potential Advantages Compared to 5-FU NuCana has Initiated a Phase Ib Study of NUC-3373 in Patients with Advanced Colorectal Cancer in Combination with Other Agents Typically Administered with
View HTML
Toggle Summary NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018
50% Objective Response Rate on Intent-to-Treat Basis Observed Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Planned EDINBURGH, United Kingdom , Oct. 21, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly
View HTML
Toggle Summary NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress
EDINBURGH, United Kingdom , Oct. 09, 2018 (GLOBE NEWSWIRE) -- NuCana plc ( NASDAQ:NCNA ), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, today announced that investigators will present new data from the Acelarin (NUC-1031)
View HTML
Toggle Summary NuCana to Participate in Citi’s 13th Annual Biotech Conference
EDINBURGH, United Kingdom , Aug. 29, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief
View HTML
Toggle Summary NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update
Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October EDINBURGH, United Kingdom , Aug. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2018 and provided an update on its extensive clinical program with its
View HTML